Prof.Dr. Berrin Pehlivan

Hakkımda

Prof. Dr. Berrin Pehlivan

Prof. Dr. Berrin Pehlivan, lisans eğitimini Hacettepe Üniversitesi Tıp Fakültesi’nde tamamladı. Ailesinde ve çevresinde sıklıkla rastladığı Kanser vakalarının motivasyonuyla kariyerini Onkoloji alanına yönlendirdi.

Uluslararası Deneyim ve Uzmanlık

Pehlivan, tıp eğitimi sırasında staj dönemini geçirdiği Boston Üniversitesi Radyasyon Onkolojisi Bölümü’nde gözlemlerde bulunarak uluslararası vizyonunu şekillendirdi. Ardından Hacettepe Üniversitesi’nde tamamladığı Radyasyon Onkolojisi uzmanlık eğitiminin ardından uzun yıllar yurt dışında kalarak kendisini geliştirdi.

Kanserle mücadelede küresel teknolojiler hakkında araştırmalar yaparak sürekli kendini yenileyen Prof. Dr. Pehlivan, 2004 – 2009 yılları arasında Fransa ve İsviçre’de birçok bilimsel çalışmada aktif rol aldı. Çalışmalarını;

  • Fransa Avrupa Kanseroloji Programı’nda,
  • Lozan Üniversitesi Radyasyon Onkolojisi Ana Bilim Dalı’nda,
  • İsviçre Villigen Paul Scherrer Enstitüsü Proton Terapi Merkezi’nde ve
  • Fransa Orsay Proton Terapi Merkezi’nde sürdürdü.

Türkiye'ye Dönüş ve Kurucu Rolleri

Edindiği zengin deneyimleri ilk elden kendi insanlarıyla paylaşmak üzere Türkiye’ye dönen Pehlivan, sırasıyla Başkent Üniversitesi ve Akdeniz Üniversitesi Tıp Fakültesi’nde önemli çalışmalara imza attı.

Ardından Memorial Sağlık Grubu bünyesindeki Medstar Antalya Hastanesi Radyasyon Onkolojisi Bölümü’nü kurdu.

Akademik ve Medya Katkıları

Ulusal ve uluslararası alanda birçok makale, bilimsel yayın ve projeye imza atan Pehlivan, 2018 yılı sonuna kadar Medical Park Bahçelievler Hastanesi, Medical Park Göztepe Hastanesi ve Altınbaş Üniversitesi’nde çalışmalarını sürdürdü.

Ayrıca;

  • “50 Soruda Kanser” Kitabının yazarıdır.
  • Milliyet Gazetesi Cadde Eki’nde Bilim Köşesi adı altında düzenli olarak yazılar kaleme almaktadır.

Mevcut Görevleri

Prof. Dr. Berrin Pehlivan, halen çalışmalarına şu kurumlarda devam etmektedir:

  • Bahçeşehir Üniversitesi Radyasyon Onkolojisi Anabilim Dalı’nda Öğretim Üyesi olarak geleceğin bilim insanlarını yetiştirmektedir.
  • Viyana/Avusturya’daki MedAustron Partikül Terapi Merkezi’nde Danışman Hekim olarak görev yapmaktadır.
  • Kurucusu olduğu BP Klinik’te çalışmalarını sürdürmektedir.

Akademik Kariyer ve Öğrenim Durumu

DereceBölüm/ProgramÜniversiteYıl
LisansTıp FakültesiHacettepe Üniversitesi1993
UzmanlıkRadyasyon OnkolojisiHacettepe Üniversitesi2001
Yüksek LisansMBA (Master for Business Administration)Antalya Bilim Üniversitesi2014-2016

Mesleki Görevler ve Uluslararası Deneyim

Temel Görevler:

  • Temmuz 2018 – Günümüz: Prof. Dr., Bahçeşehir Üniversitesi, Radyasyon Onkolojisi (Öğretim Üyesi)

  • Mayıs 2017 – Haziran 2018: Prof. Dr., Radyasyon Onkolojisi, Medical Park Hastaneleri (Göztepe/Bahçelievler) & Altınbaş Üniversitesi

  • Nisan 2015 – Mayıs 2017: Doç. Dr., Radyasyon Onkolojisi, Medical Park Hastaneleri & Altınbaş Üniversitesi

  • Nisan 2012 – Şubat 2015: Doç. Dr., Radyasyon Onkolojisi, Memorial Sağlık Grubu Medstar Antalya Hastanesi

  • Mart 2010 – Nisan 2012: Yrd. Doç. Dr., Radyasyon Onkolojisi, Akdeniz Üniversitesi, Antalya

Uluslararası ve Araştırma Görevleri:

  • 2011: Türk Radyasyon Onkolojisi Derneği Yeterlilik

  • Nisan 2008 – Ekim 2008: Misafir Bilim İnsanı, Institute Curie Orsay Protonterapi Merkezi, Orsay/Fransa

  • Ağustos 2007 – Mart 2008: Misafir Bilim İnsanı, Protonterapi Merkezi, Paul Scherrer Enstitüsü, Villigen/İsviçre

  • Kasım 2004 – Mart 2006: Araştırma Görevlisi, Avrupa Kanseroloji Diploma Programı (DUERCC), Institute Gustave Roussy, Paris, Fransa

Bilimsel Yayınlar

  1. Somay E, Topkan E, Bascil S, Kılıc Durankuş N, Senyürek Ş, Ozturk D, Pehlivan B, Selek U. Global Immune-Nutrition-Inflammation Index as a novel comprehensive biomarker in predicting the radiation-induced trismus rates in locally advanced nasopharyngeal carcinoma patients. Biomol Biomed. 2024 Jun 10 Global Immune-Nutrition-Inflammation Index as a novel comprehensive biomarker in predicting the radiation-induced trismus rates in locally advanced nasopharyngeal carcinoma patients – PubMed (nih.gov)
  2. Topkan E, Kucuk A, Ozturk D, Ozkan EE, Besen AA, Pehlivan B, Selek U. Prognostic Value of Novel CARWL Score in Stage IIIC Non-Small-Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy. Can Respir J. 2024 Jun 28;2024:2803044. Prognostic Value of Novel CARWL Score in Stage IIIC Non-Small-Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy – PubMed (nih.gov)
  3. Somay E, Topkan E, Selek U, Pehlivan B. Comment on ‘accelerated hypofractionated chemoradiation for locally advanced head and neck cancer during COVID-19 pandemic: A tertiary care experience’. J Cancer Res Ther. 2024 Apr 1;20(3):1106-1107 Comment on ‘accelerated hypofractionated chemoradiation for locally advanced head and neck cancer during COVID-19 pandemic: A tertiary care experience’ – PubMed (nih.gov)
  4. Somay E, Topkan E, Kucuk A, Ozturk D, Ozkan EE, Ozdemir BS, Besen AA, Mertsoylu H, Pehlivan B, Selek U. Pre-chemoradiotherapy high platelet counts predict jaw osteoradionecrosis in locally advanced nasopharyngeal carcinoma patients. J Stomatol Oral Maxillofac Surg. 2024 Mar 20:101838. Pre-chemoradiotherapy high platelet counts predict jaw osteoradionecrosis in locally advanced nasopharyngeal carcinoma patients – PubMed (nih.gov)
  5. Somay E, Topkan E, Selek U, Pehlivan B. Comment on ” Impact of pretreatment quality of life on tolerance and survival outcome in head and neck cancer patients undergoing definitive CCRT”. J Formos Med Assoc. 2024 Feb 26:S0929-6646(24)00137-2. Comment on ” Impact of pretreatment quality of life on tolerance and survival outcome in head and neck cancer patients undergoing definitive CCRT” – PubMed (nih.gov)
  6. Yilmaz B, Somay E, Topkan E, Pehlivan B, Besen AA, Mertsoylu H, Selek U. Predictive potential of pan-immune-inflammation value / hemoglobin index as biomarker for osteoradionecrosis risk in locally advanced nasopharyngeal carcinomas. J Stomatol Oral Maxillofac Surg. 2024 Jan 28;125(6):101786.
  7. Somay E, Topkan E, Pehlivan UA, Yilmaz B, Besen AA, Mertsoylu H, Pehlivan B, Selek U. The Use of Pre-Chemoradiotherapy Total Masseter Muscle Volume as a Novel Predictor of Radiation-Induced Trismus in Locally Advanced Nasopharyngeal Carcinoma Patients. 2024 Jan 10;10(1):79-89.
  8. Topkan E, Somay E, Pehlivan B, Selek U. Comment on Konishi et al. Oral Radiol. 2024 Apr;40(2):327-328. Comment on Kittichet et al. (doi: 10.1111/odi.14905) – PubMed (nih.gov)
  9. Topkan E, Kucuk A, Ozkan EE, Ozturk D, Besen AA, Mertsoylu H, Pehlivan B, Selek U. High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer. Discov Oncol. 2023 Dec 13;14(1):230.
  10. Topkan E, Somay E, Selek U, Pehlivan B. Letter re: Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial. Eur J Cancer. 2024 Mar;200:113459.
  11. Yilmaz B, Somay E, Topkan E, Pehlivan B, Selek U. Pre-chemoradiotherapy low hemoglobin levels indicate increased osteoradionecrosis risk in locally advanced nasopharyngeal cancer patients. Eur Arch Otorhinolaryngol. 2023 Feb 7. Pre-chemoradiotherapy low hemoglobin levels indicate increased osteoradionecrosis risk in locally advanced nasopharyngeal cancer patients – PubMed (nih.gov)
  12. Somay E, Yilmaz B, Topkan E, Kucuk A, Pehlivan B, Selek U. Initial neutrophil-to-lymphocyte ratio predicts radiation-induced trismus in parotid gland cancer. Oral Dis.2022 Nov 8. Initial neutrophil-to-lymphocyte ratio predicts radiation-induced trismus in parotid gland cancer – PubMed (nih.gov)
  13. Somay E, Yilmaz B, Topkan E, Kucuk A, Haksoyler V, Pehlivan B, Selek U, Araz K. Hemoglobin-to-platelet ratio in predicting the incidence of trismus after concurrent chemoradiotherapy. Oral Dis 2022 Aug 29. Hemoglobin-to-platelet ratio in predicting the incidence of trismus after concurrent chemoradiotherapy – PubMed (nih.gov)
  14. Topkan E, Selek U, Kucuk A, Pehlivan B. Low Pre-Chemoradiotherapy Pan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas. J Inflamm Res. 2022 Sep 18;15:5413-5423. Low Pre-Chemoradiotherapy Pan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas – PubMed (nih.gov)
  15. Topkan E, Selek U, Haksoyler V, Kucuk A, Durankus NK, Sezen D, Bolukbasi Y, Pehlivan B. Postchemoradiotherapy Neutrophil-to-Lymphocyte Ratio Predicts Distant Metastasis and Survival Results in Locally Advanced Pancreatic Cancers. Int J Clin Pract. 2022 Jan 31;2022:7473649. Postchemoradiotherapy Neutrophil-to-Lymphocyte Ratio Predicts Distant Metastasis and Survival Results in Locally Advanced Pancreatic Cancers – PubMed (nih.gov)
  16. Yalcin K, Pehlivan B, Celen S, Bas EG, Kabakci C, Pashayev D, Daloglu H, Zhumatayev S, Uygun V, Karasu GT, Hazar V, Yesilipek A. Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. J Pediatr Hematol Oncol2021 Mar 31. Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL – PubMed (nih.gov)
  17. Kucuk A, Topkan E, Selek U, Haksoyler V, Mertsoylu H, Besen AA, Pehlivan B. High Measures of Pre-Chemoradiotherapy Platelet-to-Albumin Ratio Indicates Poor Prognosis in Locally Advanced Pancreatic Cancer Patients. Ther Clin Risk Manag. 2022 Apr 14;18:421-428. High Measures of Pre-Chemoradiotherapy Platelet-to-Albumin Ratio Indicates Poor Prognosis in Locally Advanced Pancreatic Cancer Patients – PubMed (nih.gov)
  18. Topkan E, Selek U, Küçük A, Haksöyler V, Özdemir Y, Sezen D, Mertsoylu H, Besen AA, Bölükbaşı Y, Özyılkan O, Pehlivan B. Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis. J Oncol 2021 Jan 23;2021. Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis – PubMed (nih.gov)
  19. Küçük A, Ozkan EE, Öztep SE, Mertsoyle H, Pehlivan B, Selek U, Topkan E. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. J Oncol 2020 Dec 16. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy – PubMed (nih.gov)
  20. Topkan E, Besen AA, Mertsoylu H, Kucuk A, Pehlivan B, Selek U. Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide. Int J Inflam. 2020 Jun 8;2020.
  21. Topkan E, Mertsoylu H, Kucuk A, Besen AA, Sezer A, Sezen D, Bolukbasi Y, Selek U, Pehlivan B. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy. Gastroenterol Res Pract. 2020 Jul 30;2020.
  22. Topkan E, Ozdemir Y, Guler OC, Kucuk A, Besen AA, Mertsoylu H, Sezen D, Akdemir EY, Sezer A, Bolukbasi Y, Pehlivan B, Selek U. Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study. J Oncol. 2020 Sep 4;2020.
  23. Topkan E, Kucuk A, Ozdemir Y, Mertsoylu H, Besen AA, Sezen D, Bolukbasi Y, Pehlivan B, Selek U. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol. J Immunol Res. 2020 Nov 14;2020.
  24. Kucuk A, Ozkan EE, Eskici Oztep S, Mertsoylu H, Pehlivan B, Selek U, Topkan E. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. J Oncol2020 Dec 16;2020. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy – PubMed (nih.gov)
  25. Topkan E, Besen AA, Ozdemir Y, Kucuk A, Mertsoylu H, Pehlivan B and Selek U. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Post-neurosurgical Radiotherapy plus Concurrent and Adjuvant Temozolomide. Mediators Inflamm. 2020 23;2020. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide – PubMed (nih.gov)
  26. Kucuk A, Topkan E, İkiz ED, Durankuş N, Senyurek S, Aydemir EY, Sezen D, Bolukbaşı Y, Selek U, Pehlivan B. Combination of stereotactic radiosurgery with immunotherapy: is it a new treatemnt option for brain metastases? Advancements in Cancer Research
  27. Topkan E, Küçük A, Şenyürek S, Sezen D, Durankuş NK, Aydemir EY, İkiz ED, Bölükbaşı Y, Pehlivan B ve Selek U. Preoperative radiosurgery in management of brain metastases. J Cancer Tumor Int, 10(1):1-11, 2020. Preoperative radiosurgery in management of brain metastases. J Cancer Tumor Int, 10(1):1-11, 2020.
  28. Topkan E, Küçük A, Sezen D, Senyürek S, Aydemir EY, Durankuş N, İkiz ED, Bolükbaşı Y, Pehlivan B ve Selek U. A review on brain metastases prognostic scoring systems. New Frontiers in Med and Med Res Vol.1, 2 August 2021, Page 92-107.
  29. Topkan E, Küçük A, Şenyürek Ş, Sezen D, Durankuş NK, Akdemir EY, Bölükbaşı Y, Pehlivan B, Selek U. Preoperative radiosurgical management of brain metastasis: Evidence and Challenges Advancement in Caancer Research, 2023, p:75-91.
  30. Sağlam Y, Bölükbaşı Y, Atasoy Aİ, Karaköse F, Alpan V, Selek U, Küçük A, Pehlivan B, Topkan E. Quality assurance in stereotactic radiosurgery and stereotactic body radiotherapy. Advances in Research 21 (7), 22-33.
  31. Bölükbaşı Y, Selek U, Sezen D, Durankuş NK, Akdemir EY, Şenyürek Ş, Küçük A, Pehlivan B, Topkan E. Tumor cavity stereotactic radiosurgery for resected brain metastases. JCTI 2020, 10(2):15-30. Tumor Cavity Stereotactic Radiosurgery for Resected Brain Metastases (journaljcti.com)
  32. Pehlivan B, Sengul K, Yesil A, Nalbant N, Ozturk O, Ozdemir Y, Topkan E. Dosimetric comparison of lung-sparing radiation therapy between volumetric arc therapy and helical tomotherapy for unresectable malignant pleural mesothelioma. BioMed Res Int, 2019. Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma – PubMed (nih.gov)
  33. Pehlivan B, Kucuk A, Mertsoylu H, Topkan E. Current management of brainstem gliomas. Int. J.Adv. Res. 7(9), 2019. journalijar.com/uploads/268_IJAR-28789.pdf
  34. Topkan E, Pehlivan B. Radiation-induced abscopal effects on cardiovascular system. IndJMedResPharmSci, 6(9), 2019. (PDF) Theoretical Bases of the Influence of Radiation-induced Abscopal Effects on the Cardiovascular System (researchgate.net)
  35. Golusinski P, Di Maio P, Pehlivan B, Colley S, Nankivell P, Kong A, Hartley A, Mehanna H. Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncol. 2019 Jan;88:145-152. Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck – PubMed (nih.gov)
  36. Topkan E, Selek U, Ozdemir Y, Besen AA, Guler OC, Yildirim BA, Mertsoylu H, Findikcioğlu A, Ozyılkan O, Pehlivan B. Risk factors for .fatal pulmonary hemorrahage following concurrent chemoradiotherapy in stage 3B/C squamous-cell lung carcinoma patients. J Oncol 2018 Nov 1;2018. Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell Lung Carcinoma Patients – PubMed (nih.gov)
  37. Topkan E, Yildirim BA, Guler OC, Parlak C, Pehlivan B, Selek U. Safety and palliative efficacy of single-dose-8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):774-80. Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy – PubMed (nih.gov)
  38. Mirimanoff RO, Ozsahin M, Thariat J, Ozyar E, Schick, Pehlivan B, Krengli M, Pellanda AF, Vess H. Cai L, Scandolaro L, Belacemi Y, Villa S, Igdem S, Lutsyk M, Miller RC. History of rare cancer network and past research. Rare Tumors. 2014 Aug 6;6(3):5462. History of the rare cancer network and past research – PubMed (nih.gov)
  39. Sarıca FB, Cekinmez M, Tufan K, Sen O, Onal HC, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Altinors B. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and efeectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma. Asian J Neurosurg. 2012 Oct;7(4):181-90. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma – PubMed (nih.gov)
  40. Topkan E. Parlak C, Topuk S, Pehlivan B. Influence on oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. BMC Cancer 2012 Oct 31;12:502. Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer – PubMed (nih.gov)
  41. Pehlivan B, Ares C, Lomax T, Stadelmann O, Goitein G, Timmermann B, Schneider RA, Hug EB.: Temporal lobe toxicity analyasis after proton radiation therapy for skull base tumors. Int J Radiat Oncol Biol Phys 2012 Aug 1;83(5):1432-40. Temporal lobe toxicity analysis after proton radiation therapy for skull base tumors – PubMed (nih.gov)
  42. Topkan E, Parlak C, Kotek A, Yuksel O, Cengiz M, Ozsahin M, Pehlivan B. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens. Int J Radiat Oncol Biol Phys 2012 July 15;83(4):1264-71. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens – PubMed (nih.gov)
  43. Pehlivan B, Onal C, Yavuz M.: Retinoblastoma Tedavisinde Eksternal Radyoterapinin Rolü ve Radyoterapi Seçenekleri. Int J. Hematol Oncol. 2012, 22(2):1-9.
  44. Topkan E, Parlak C, Kotek A, Yapar AF, Pehlivan B. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol 2011 10,11:123. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy – PubMed (nih.gov)
  45. Topkan E, Topuk S, Oymak E, Parlak C, Pehlivan B. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am J Clin Oncol 2012; 35(3):284-9. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide – PubMed (nih.gov)
  46. Sarıca F, Tufan K, Çekinmez M, Şen O, Onal HC, Mertsoylu H, Pehlivan B, Erdoğan B, Altınors MN. Effectiveness of temozolomide treatment used at thesame time with radiotherapyand adjuvant temozolomid: concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors. J Neurosurg Sci. 2010; 54(1): 7-19. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors – PubMed (nih.gov)
  47. Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, Azria D, Roelandts M, Kaanders JH, Cengiz M, Krengli M, Matzinger O, Zouhair A.: Outcome and prognostıc factors ın olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):992-7. Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study – PubMed (nih.gov)
  48. Yavuz MN, Topkan E, Yavuz AA, Aydin M, Onal C, Reyhan M, Kotek A, Pehlivan B, Yapar AF.: FDG-PET/CT Imaging-based taget volume delineation for preoperative conformal radiotherapy for rectal carcinoma. Int J Hematol Oncol 2010, 20(2):067-074. International Journal of Hematology and Oncology (uhod.org)
  49. Pehlivan B, Topkan E, Onal C, Nursal GN, Yüksel O, Yavuz M, Yavuz A.: Comparison of CT and integrated PET-CT based radiation therapy planning in malign plevral mesothelioma patients. Radiat Oncol. 2009, 4:35. Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma – PubMed (nih.gov)
  50. Pehlivan B, Luthi F, Matzinger O, Betz M, Dragusanu D, Bulling S, Bron L, Pasche P, Seelentag W, Mirimanoff RO, Zouhair A, Ozsahin M.: Feasibility and efficacity of accelerated weekly concomitant boost postopeartive radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer. Ann Surg Oncol. 2009, 16:1337-1343. Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer – PubMed (nih.gov)
  51. Pehlivan B, Pichenot C, Casting M, Auperin A, Arriagada R, Bourhis J.: Interfractional set-up errors evaluation by daily electronic portal imaging of IMRT in head and neck cancer patients. Acta Oncol. 2009, 48(3):440-5. Interfractional set-up errors evaluation by daily electronic portal imaging of IMRT in head and neck cancer patients – PubMed (nih.gov)
  52. Pehlivan B, Zouhair A, Luthi F, Bron L, Pasche P, Dragusanu D, Azria D, Matzinger O, Mirimanoff RO, Ozsahin M.: Decrease in hemoglobin levels following surgery influences the outcome in head and neck cancer patients treated with accelerated postoperative radiotherapy. Ann Surg Oncol. 2009, 16:1331-1336. Decrease in hemoglobin levels following surgery influences the outcome in head and neck cancer patients treated with accelerated postoperative radiotherapy – PubMed (nih.gov)
  53. Onal C, Arslan G, Topkan E, Pehlivan B, Yavuz M, Oymak E, Yavuz A.: Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: target volume coverage and organs at risk doses. J Exp Clin Cancer Res. 2009 Jul 1;28:95. Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: target volume coverage and organs at risk doses – PubMed (nih.gov)
  54. Onal C, Pehlivan B, Bal N, Topkan E, Kilinc F, Topuk S. : Sarcomatoid Carcinoma of the Urinary Bladder Treated with Adjuvant Radiotherapy: A Case Report. Clinical Medicine: Case Reports 2009:2 39-42. Sarcomatoid carcinoma of the urinary bladder treated with adjuvant radiotherapy: a case report – PubMed (nih.gov)
  55. Onal C, Yuksel O, Topkan E, Pehlivan B. : Bilateral glomus tumor treated with PET-CT based conformal radiotherapy: case report. Cases Journal 2009, 2:8402. Bilateral glomus tumor treated with PET-CT based conformal radiotherapy: a case report – PubMed (nih.gov)
  56. Atahan IL, Yıldız F, Ozyar E, Pehlivan B, Genç M, Köse M, Tulunay G, Ayhan A, Yuce K, Güler N, Kucukali T.: Radiotherapy in the adjuvant setting of cervical carcinoma: treatment, results, and prognostic factors. Int J Gynecol Cancer 2007, 17 (4): 813-820. Radiotherapy in the adjuvant setting of cervical carcinoma: treatment, results, and prognostic factors – PubMed (nih.gov)
  57. Garcia R, Bourhis J, Pehlivan B, Pichenot C, Alfonsi M.: Intensity modulated radiotherapy for cancers of the upper aerodigestive tract. Cancer Radiother 2007, 11(6-7):353-7. [Intensity modulated radiotherapy for cancers of the upper aerodigestive tract] – PubMed (nih.gov)
  58. Pehlivan B, Topkan E, Yavuz A.: Protonterapy in clinical use. Ege Tıp Dergisi, 50(1):1-6, 2011. [PDF] Proton therapy in clinical use | [PDF] Klinik proton terapi uygulamaları (acarindex.com)